. . . . . . . . . . . "Rapidly absorbed following oral administration."@en . . "51803-78-2"@en . . . . "1.8\u20134.7 hours"@en . . . . . . . . "Oral TDLO (human): 1.429 mg/kg; Oral TDLO (woman): 2 mg/kg; Oral LD50 (rat): 200 mg/kg; Oral LD50 (mouse): 392 mg/kg"@en . "The therapeutic effects of Nimesulide are the result of its complete mode of action which targets a number of key mediators of the inflammatory process such as: COX-2 mediated prostaglandins, free radicals, proteolytic enzymes and histamine."@en . "Humans and other mammals"@en . . . " "@en . ">97.5%"@en . "Renal (50%), fecal (29%)"@en . "Nimesulide"@en . "Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old. Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries."@en . . "For the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old."@en . . . . . . . "withdrawn"@en . . . . . . . "Bernard Pirotte, Geraldine Piel, Philippe Neven, Isabelle Delneuville, Joszef Geczy, \"Water-soluble nimesulide salt and its preparation, aqueous dolution containing it, nimesulide-based combinations and their uses.\" U.S. Patent US5756546, issued November, 1991."@en . .